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Abstract
In the N-end rule pathway of protein degradation, the destabilizing activity of N-terminal Asp, Glu or (oxidized) Cys residues
requires their conjugation to Arg, which is recognized directly by pathway’s ubiquitin ligases. N-terminal arginylation is
mediated by the Ate1 arginyltransferase, whose physiological substrates include the Rgs4, Rgs5 and Rgs16 regulators of G
proteins. Here, we employed the Cre-lox technique to uncover new physiological functions of N-terminal arginylation in
adult mice. We show that postnatal deletion of mouse Ate1 (its unconditional deletion is embryonic lethal) causes a rapid
decrease of body weight and results in early death of ,15% of Ate1-deficient mice. Despite being hyperphagic, the
surviving Ate1-deficient mice contain little visceral fat. They also exhibit an increased metabolic rate, ectopic induction of
the Ucp1 uncoupling protein in white fat, and are resistant to diet-induced obesity. In addition, Ate1-deficient mice have
enlarged brains, an enhanced startle response, are strikingly hyperkinetic, and are prone to seizures and kyphosis. Ate1-
deficient males are also infertile, owing to defects in Ate1
2/2 spermatocytes. The remarkably broad range of specific
biological processes that are shown here to be perturbed by the loss of N-terminal arginylation will make possible the
dissection of regulatory circuits that involve Ate1 and either its known substrates, such as Rgs4, Rgs5 and Rgs16, or those
currently unknown.
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Introduction
N-terminal arginylation of intracellular proteins by Arg-tRNA-
protein transferase (R-transferase) is a part of the N-end rule
pathway of protein degradation (Fig. 1A). In eukaryotes, this
pathway is a part of the ubiquitin (Ub)-proteasome system. The N-
end rule relates the in vivo half-life of a protein to the identity of its
N-terminal residue (reviewed in [1,2,3,4]). Degradation signals
(degrons) that can be targeted by the N-end rule pathway are of
two distinct kinds: N-terminal degrons, called N-degrons, and
internal (non-N-terminal) degrons [1,5]. The main determinant of
an N-degron is a destabilizing N-terminal residue of a substrate
protein (Fig. 1A). The other determinants of N-degron are a
substrate’s internal Lys residue (the site of formation of a poly-Ub
chain) and a nearby unstructured region [6,7]. An N-degron is
produced from a precursor, called a pre-N-degron, through a
protease-mediated cleavage of a substrate that exposes a
destabilizing N-terminal residue.
The N-end rule has a hierarchic structure (Fig. 1A). N-terminal
Asn and Gln are tertiary destabilizing residues in that they
function through their enzymatic deamidation, to yield the
secondary destabilizing N-terminal residues Asp and Glu [8].
Destabilizing activity of N-terminal Asp and Glu requires their
conjugation to Arg, one of the primary destabilizing residues, by
the Ate1-encoded R-transferase [9,10,11,12]. In eukaryotes that
produce nitric oxide (NO), R-transferase arginylates not only N-
terminal Asp and Glu but also Cys, after its conversion to Cys-
sulfinate or Cys-sulfonate, in reactions that require NO and
oxygen (Fig. 1A) [11,13]. Alternative splicing of the mammalian
Ate1 pre-mRNA produces isoforms of R-transferase, a metaboli-
cally unstable protein whose enzymatic activity and the in vivo
half-life are down-regulated by heme [10,12,14]. E3 Ub ligases of
the N-end rule pathway are called N-recognins. An N-recognin is
an E3 that can recognize (target for polyubiquitylation) at least a
subset of N-degrons (Fig. 1A) [1,4]. Some of substrate-binding sites
of an N-recognin target N-degrons, while other sites of the same
N-recognin are specific for structurally unrelated internal (non-N-
terminal) degrons [15,16]. At least four N-recognins, Ubr1, Ubr2,
Ubr4 and Ubr5, mediate the mammalian N-end rule pathway
(Fig. 1A) [4,17].
The functions of the N-end rule pathway in eukaryotes include
selective degradation of misfolded proteins; the sensing of heme,
oxygen, nitric oxide (NO), and short peptides; the regulation of
DNA repair and peptide import; the signaling by transmembrane
receptors, through the NO/O2-controlled degradation of G-
protein regulators Rgs4, Rgs5 and Rgs16; the fidelity of
chromosome segregation; regulation of apoptosis, meiosis, sper-
matogenesis, neurogenesis, and cardiovascular development; the
functioning of specific organs, in particular the brain and the
pancreas; and regulation of leaf senescence, seed germination, and
other processes in plants ([2,12,16,18,19,20], and refs. therein). A
partial N-terminal arginylation of the apparently long-lived
PLoS ONE | www.plosone.org 1 November 2009 | Volume 4 | Issue 11 | e7757mammalian a-actin [21] suggests that arginylation of some
proteins may not alter their in vivo half-lives.
Although there are many putative intracellular substrates of the
Ate1 R-transferase, for example, among C-terminal fragments of
proteins that are cleaved in vivo by proteases such as MetAPs,
caspases, calpains or secretases, the set of definitively identified
Ate1 substrates is still small. It includes the Drosophila
antiapoptotic Ub ligase DIAP1 [22]; the mammalian G-protein
regulators Rgs4, Rgs5 and Rgs16 [11,13]; and the separase-
produced fragment of the mammalian Rad21/Scc1 cohesin
subunit that bears N-terminal Glu, a secondary destabilizing
residue (Fig. 1A) (J. Zhou, D. Pati and A.V., unpublished data)
Figure 1. Postnatal ablation of the mouse Ate1 R-transferase, a component of the N-end rule pathway. (A) The mammalian N-end rule
pathway. N-terminal residues are indicated by single-letter abbreviations for amino acids. Yellow ovals denote the rest of a protein substrate.
‘‘Primary’’, ‘‘secondary’’ and ‘‘tertiary’’ denote mechanistically distinct subsets of destabilizing N-terminal residues (see Introduction). C* denotes
oxidizedCys,eitherCys-sulfinateorCys-sulfonate.MetAPs,Met-aminopeptidases.(B)BidirectionalpromoterbetweenthemouseAte1exons 1A and 1B[14].
Green arrows indicate transcriptional units, including a previously uncharacterized gene, termed Dfa (‘‘divergent of Ate1), that is transcribed from the
bidirectional promoter. (C) Immunoblotting-based comparisonsofAte1 levels in the indicated mouse tissues fromAte1
+/+ and Ate1
flox/2;CaggCreER mice 76
days after the tamoxifen (TM)-induced, Cre-mediated Ate1
floxRAte1
2 conversion that yielded Ate1-deficient mice. The band of 60-kDa Ate1, detected by
antibody to mouse Ate1, is indicated on the right. Total (Ponceau-stained) protein patterns are shown below, with positions of molecular-mass markers on
the left. (D) IB assays for thelevels of Ate1 and Rgs4 (25 kDa) in brain extracts from Ate1
+/+ and Ate1-deficient mice (Ate1
flox/2;CaggCreER mice 30 days after
TM treatment).
doi:10.1371/journal.pone.0007757.g001
Ablation of R-Transferase
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+/2 mice appear indistinguishable from
their wild-type counterparts, whereas Ate1
2/2 mice die around
embryonic day 15 (E15) with abnormalities that include
cardiovascular defects [10].
To bypass the embryonic lethality of nonconditional Ate1
2/2
mice, we employed the Cre-lox technique [24]. As shown below, a
systemic postnatal deletion of the sole active Ate1
flox allele in
juvenile Ate1
flox/2 mice causes a rapid decrease of body weight and
results in early death of ,15% of Ate1-deficient mice, with
surviving mice attaining only ,70% of normal weight. This failure
to thrive occurs despite higher than normal food intake by Ate1-
deficient mice. These mice contain little or no visceral fat, exhibit
an increased metabolic rate, a decreased fasting blood glucose
level, and an increased intestinal import and retention of amino
acids and/or peptides. Ate1-deficient mice are also resistant to
diet-induced obesity and exhibit ectopic induction of the Ucp1
uncoupling protein in white adipose tissue (WAT). In addition,
Ate1-deficient mice have enlarged brains, an enhanced startle
response, and are strikingly hyperkinetic. They often suffer from
kyphosis, i.e., an excessive curvature of the upper back, and from
frequent seizures as well. Ate1-deficient males are also infertile,
owing to defects in meiotic Ate1
2/2 spermatocytes. The
remarkably broad range of specific biological processes that are
shown here to be perturbed by the loss of N-terminal arginylation
will facilitate the dissection of regulatory circuits that involve Ate1
and either its known substrates, such as Rgs4, Rgs5 and Rgs16
[11,13], or those currently unknown.
Results
Ate1
flox/2 Mouse Strains and Production of Ate1
2/2 Mice
Standard methods were employed to produce, initially, ATE
flox/+
mouse strains in which a specific segment of Ate1 was ‘‘floxed’’, i.e.,
flanked by 34-bp loxP repeats (Fig. 2C–E). The targeting vector
contained ,14 kb of Ate1, including the exon 1A-exon 4 segment
that encodes an essential part of R-transferase [9] (Fig. 2A). Our
previous work has shown that the Ate1 promoter (PAte1)i s
bidirectional, expressing both Ate1 and an oppositely oriented gene
termed Dfa (divergent from Ate1), which overlaps with exon 1A of
Ate1 (Fig. 1B) ([14]; C.S.B. and A.V., unpublished data). To
minimize the possibility of perturbing the expression of Dfa, the
‘‘floxed’’regionof Ate1 encompassedexons2–4,away from exon 1A
(Fig. 1B). Ouraimwasto produce ATE
flox/2 mousestrains that were
‘‘poised’’ to lose their remaining active ATE
flox allele through the
expression of Cre recombinase. To do so, heterozygous matings
were carried out among the above ATE
flox/+ mice, the previously
constructed ATE
+/2 mice [10], and a mouse strain that contained
theCaggCreERgene,expressedfromtheubiquitouslyactivechimeric
Cagg promoter [25]. CaggCreER encoded CreER, a fusion between
Cre and a derivative of the mouse estrogen receptor ligand binding
domain. CreER was functionally inactive (sequestered in the
cytosol) but could be activated by intraperitoneal (IP) injections of
tamoxifen (TM) [25]. Depending on configurations of their Ate1
alleles, the resulting mice, poised for the loss of Ate1, were termed
Ate1
flox/2;CaggCreER or Ate1
flox/flox;CaggCreER.
Using standard methods, we could demonstrate the presence of
Ate1
flox/2;CaggCreER mice, at expected (Mendelian) frequencies, in
the progeny of above matings. These mice expressed TM-inducible
CreERrecombinaseandcontainedasinglecopyofAte1
flox,th eact iv e
Ate1 allele (Figs. 2 and 3A). The functional intactness of Ate1
flox was
inferred from the fact that Ate1
flox/2;CaggCreER mice survived
embryogenesis (in contrast to Ate1
2/2 mice [10]) and were
phenotypically similar (in the absence of TM treatment) to Ate1
+/2
and Ate1
+/+ mice. To induce the Ate1
floxRAte1
2 conversion, ,1
month old Ate1
flox/2;CaggCreER mice and their Ate1
flox/+;CaggCreER
(as well as Ate1
+/2;CaggCreER) littermates, used as controls, were
treated with TM (see Materials and Methods for details, including
the ages of TM-treated mice). Southern hybridization and PCR-
based analyses of DNA from tissues of the resulting mice (sampled
,1 month after TM treatment) confirmed the TM-induced, Cre-
mediated excision of the Ate1
flox allele in Ate1
flox/2;CaggCreER mice.
The frequency of Ate1
floxRAte1
2 conversion was nearly 100% in the
brain and kidney of these mice, but significantly lower in several
other tissues (Figs. 2G, H and 3B).
We also used an affinity-purified antibody to mouse Ate1 [11] to
carry out immunoblotting (IB) with extracts from brain, heart,
kidney, liver, muscle, brown adipose tissue (BAT) and white
adipose tissue (WAT) that were harvested up to 8 months after
TM treatment of Ate1
flox/2;CaggCreER mice, versus identically TM-
treated control littermates. No Ate1 could be detected by IB in
several tissues of TM-treated Ate1
flox/2;CaggCreER mice, in contrast
to readily detectable Ate1 in TM-treated control mice (Fig. 1C).
The only significant exception was liver (Fig. 1C, lanes 7, 8; cf.
lanes 5, 6 or lanes 11–14; see also below). One effect of Ate1
depletion in the mouse brain was a striking increase of Rgs4, a
physiological Ate1 substrate (see Introduction) that down-regulates
specific G proteins by acting as a GTPase-activating protein (GAP)
(Fig. 1D). Whereas no Rgs4 could be detected in the Ate1-
containing brain (owing to degradation of Rgs4 by the N-end rule
pathway [11]), an intense band of Rgs4 was present in the Ate1-
deficient brain, illustrating high penetrance of Ate1 deletion in the
brain (Fig. 1D).
We also performed in vitro arginylation assays with extracts
from several tissues of Ate1
flox/2;CaggCreER mice 21 days after TM
treatment, versus extracts from identically treated Ate1
+/+ or
ATE1
+/2 mice. The TM-induced decrease of arginylation activity
in specific organs of Ate1
2/2;CaggCreER mice ranged from ,90%
in the brain and kidney to ,60% in the liver (Fig. 3C–E).
Although heterozygous Ate1
+/2 mice were phenotypically similar
to their wild-type (Ate1
+/+) counterparts, we found that Ate1
+/2
mice grew slightly but consistently slower than Ate1
+/+ mice, and
reached a lower average weight (Fig. 4B). In agreement with this
mild but detectable haploinsufficiency of Ate1, the arginylation
activity in extracts from, e.g., brains or hearts of Ate1
+/2 mice was
significantly below its wild-type (Ate1
+/+) levels (Fig. 3C), implying
the absence of a compensatory (e.g., autoregulated) increase of
Ate1 expression upon a decrease of Ate1 gene dosage.
Retarded Growth, Kyphosis, and a Transient Increase in
Lethality of Ate1-Deficient Mice
TM treatment produced abnormal phenotypes within 1 week in
Ate1
flox/2;CaggCreER mice, in comparison to identically TM-
treated controls. Specifically, ,1 month old and previously
growing Ate1
flox/2;CaggCreER mice failed to thrive (in com-
parison to control mice) after their TM-induced conversionto
Ate1
2/2;CaggCreER mice (Figs. 4A–C and 5A). During the first ,3
weeks after becoming Ate1
2/2, these mice experienced a rapid loss
of weight and decreased growth (Fig. 4A, B), despite no decrease in
their consumption of food (see below). The average body length
(measured from tip-of-nose to base-of-tail) of Ate1
2/2;CaggCreER mice
was 5% smaller (p,0.08) than that of their Ate1-containing, identically
TM-treated counterparts (Ate1
+/+;CaggCreER, Ate1
+/2;CaggCreER,o r
Ate1
flox/+;CaggCreER mice) (Figs. 4D and 5C).
In the entire cohort of TM-treated post-natal Ate1
flox/2;CaggCreER
mice, 15% of them (18 of 119 mice) died over 42 days after TM
treatment. Crucially, none of identically TM-treated control mice
(Ate1
+/+;CaggCreER, Ate1
+/2;CaggCreER,o rAte1
flox/+;CaggCreER)d i e di n
t h es a m et i m ei n t e r v a l .T h ef r e q u e n c yo fAte1
2/2;CaggCreER mice
Ablation of R-Transferase
PLoS ONE | www.plosone.org 3 November 2009 | Volume 4 | Issue 11 | e7757Figure 2. Genomic configurations at the Ate1 locus of Cre-lox-based mouse strains constructed in the present work. (A) The 59 end of
the previously produced unconditional Ate1
2 allele [10], in which the Ate1 exons 1b through 3 were replaced by a cassette encoding a promoter-
lacking, NLS-containing LacZ (NLS-bgal) (it was expressed from the endogenous PAte1 promoter) and the Neo selection marker expressed from the
phosphoglycerate kinase PPGK promoter (green rectangles). (B) A diagram of the 59 end of wild-type (wt) mouse Ate1, indicating approximate
locations of exons 1a through 5. (C) The ,22.5 kb targeting construct containing a ,6 kb long-arm region of Ate1 homology (shown as a shaded
rectangle on the left); a single loxP site (red triangle) upstream of Ate1 exon 2, a ‘‘floxed’’-hygromycin-resistance (hph) cassette, expressed from the
PPGK promoter (blue arrow between two red triangles) downstream of Ate1 exon 4; a ,2 kb short-arm region of homology (an inclined shaded
rectangle), and the HSV thymidine kinase (tk) negative-selection cassette expressed from the PHSV promoter (yellow arrow). Wavy line indicates an
abutting sequence of the pBR322 plasmid DNA. (D) The tri-lox Ate1 allele obtained after a correctly targeted double crossover event. (E) In the
notations here and elsewhere in the paper, ‘‘flox-on’’ indicates a configuration depicted in this panel (the functionally active Ate1
flox allele), whereas
‘‘flox-off’’ indicates a configuration depicted in panel F (the null Ate1
2 allele). The functionally active, ‘‘flox-on’’ (Ate1
flox) allele, obtained by the
removal of the hph cassette, using the in vivo expression of Cre-recombinase driven by the PEIIA promoter, which is active only in pre-implantation
blastocysts. (F) The null ‘‘flox-off’’ (Ate1
2) allele obtained by the inducible expression of CreER recombinase from the PCagg promoter and
posttranslationally induced by tamoxifen (TM) treatment (see the main text and Materials and Methods). H, approximate locations of HindIII sites
used in Southern analyses with DNA probe A (see panel G); E, approximate locations of EcoRI sites used in Southern analyses with DNA probe D (see
panel H); black boxes marked ‘‘A’’ and ‘‘D’’ indicate the regions specific for DNA probes A and D, respectively. (G) Southern hybridization analysis
using DNA probe A and HindIII-digested genomic DNA. The wt Ate1 allele (panel B) yields the 11.8 kb HindIII fragment. The previously constructed [10]
unconditionally null Ate1
2 allele (panel A), denoted as ‘‘null’’ on this panel, yields the 9.8 kb HindIII fragment. The functionally active flox-on (Ate1
flox) allele
(panel E) yields the 6.3 kb HindIII fragment. Lane 1, Ate1
+/+;l a n e2 ,Ate1
+/2;l a n e3 ,Ate1
+/2;l a n e4 ,Ate1
flox/2. (H) Southern hybridization analysis using DNA
probe D (external to targeting vector) and EcoRI-digested genomic DNA. The previously constructed [10] unconditionally null Ate1
2allele (denoted as ‘‘null’’)
yields the 5.8 kb fragment. Both the wild-typeAte1allele and the flox-on (Ate1
flox) allele yield the 9.7 kBfragment, whereas the null flox-off (Ate1
2)alleleyields
the characteristic 3.8 kb fragment. TheuseofDNA probeDand EcoRI-digested DNA from specific tissues of tamoxifen (TM)-treated Ate1
flox/2;CaggCreER mice
allowed approximate estimates of the levels of Cre-mediated recombination that produced the flox-off (Ate1
2) allele. For example, whereas no flox-on
(Ate1
flox) allele could be detected in the kidney and brain of Ate1
flox/2;CaggCreER mice after TM treatment (lanes 5, 6), approximately equal amounts of flox-on
(Ate1
flox) and flox-off (Ate1
2) alleles were present in the heart of TM-treated Ate1
flox/2; CaggCreER mice. Lanes 1–3, 1,000, 250, and 25 ng of EcoRI-digested wt
mouse genomic DNA (from a tail biopsy), respectively. Lane 4, EcoRI-digested genomic DNA from the tail of a previously constructed [10] Ate1
+/2 mouse.
Lanes 5–7, EcoRI-digested genomic DNA from the indicated tissues of TM-treated Ate1
flox/2;CaggCreER mice. Lane 8, same as lane 7, but from a TM-treated
Ate1
flox/2 mouse (lacking the CaggCreER transgene).
doi:10.1371/journal.pone.0007757.g002
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2/2 genotype was age-
dependent. Specifically, 46% of Ate1
2/2;CaggCreER mice younger than
30 days at the beginning of TM treatment died within 42 days after
TM treatment. In contrast, only 12% of Ate1
2/2;CaggCreER mice died
if they were older than 30 days (by up to 56 days) at the beginning of
TM treatment. Those among Ate1
2/2;CaggCreER mice that survived
for at least 42 days after TM treatment eventually resumed growth, but
the rate of growth and their maximum weight were significantly below
those parameters for identically TM-treated control mice (Fig. 4A–C).
In addition to their retarded growth (despite a higher than
normal food intake; see below), 53% of Ate1
2/2;CaggCreER mice
(95 of 180 mice) appeared ‘‘scruffy’’, and 66% of them (109 of 180)
had a kyphotic posture, i.e., an excessive curvature of the upper
back (Fig. 5B). In contrast, only 3% of Ate1-containing mice (8 of
244) were scruffy, and only 2% (5 of 244) exhibited kyphosis.
Among surviving Ate1
2/2;CaggCreER mice, 10% (8 of 80)
developed patches of red hair among their normally black hair,
in contrast to identically TM-treated Ate1-containing mice (data
not shown), suggesting a misregulation of melanocytes in Ate1-
deficient mice. The liver, spleen, intrascapular brown adipose
tissue (BAT), pancreas, and testis of Ate1
2/2;CaggCreER mice
appeared normal and were of appropriate sizes (if the smaller size
of these mice (Fig. 4C) was taken into account), whereas the brains,
hearts and kidneys of these Ate1-deficient mice were dispropor-
tionately large, in comparison to those of Ate1-containing siblings
(Fig. 5D). Intact brains of Ate1-deficient mice appeared swollen, in
comparison to brains harvested, in parallel, from identically
treated Ate1-containing siblings (Fig. 6A). In addition, Ate1-
deficient males were infertile, in agreement with defects in their
testes (Fig. 6F–I). Yet another abnormality of Ate1-deficient mice
Figure 3. Cre-mediated conversion to Ate1-null genotype in different mouse tissues. (A) PCR-based genotyping of tail DNA to detect the
Cre-mediated Ate1
floxRAte1
2 conversion of the functionally active flox-on (Ate1
flox) allele to the null Ate1
2 allele in a 27-day old Ate1
flox/2;CaggCreER
mouse immediately after the fourth (daily) intraperitoneal (IP) injection of tamoxifen (TM+), or in the absence of TM treatment (TM-). Upper panel: the
512 bp DNA fragment characteristic of the flox-on (Ate1
flox) allele and the 472 bp DNA fragment characteristic of either wild-type or the previously
constructed [10] unconditionally null Ate1
2 allele, using primers CB156 and CB157 (Table 4). Lower panel: the 470 bp DNA fragment characteristic of
the Cre-produced flox-off (Ate1
2) allele, with primers CB110 and CB157 (Table 4); and the 324 bp DNA fragment (control), amplified from theIL-2 gene
using primers IMR42 and IMR43, in the same PCR reaction. (B) The Cre-mediated Ate1
floxRAte1
2 conversion, detected by PCR (as described in panel A) in
genomic DNA isolated from the indicated tissues immediately after the fourth (daily) IP injection of tamoxifen in a 24-day old Ate1
flox/2;CaggCreER mouse.
(C) Relative in vitro arginylation activity (cpm/reaction) in extracts of the indicated tissues from a wild type mouse (Ate1
+/+) (black bar), a heterozygous
mouse (Ate1
+/2) (blue bar), and an Ate1
2/2 mouse (the latter mouse was initially Ate1
flox/2;CaggCreER) (red bar) from the same litter 76 days after TM
treatment. A white bar onthe right indicates the relative arginylation activityobtained with purified recombinant mouse Ate1 (denoted as ‘‘rAte1’’) that had
been expressed in S. cerevisiae. Shown here are ‘‘cpm/reaction’’ after subtracting ‘‘cpm/reaction’’ in the null-control (‘‘buffer alone’’) sample. The control
incorporation wasapproximatelyequaltothat observedin extractsfromspleenandthymus.Inotherwords,theassay configuredasdescribedinthispanel
and in Materials and Methods was not sensitive enough to robustly detect the arginylation activity in extracts from spleen and thymus. (D) Relative in vitro
arginylation activity (cpm/reaction) in the whole brain, cerebellum, and hippocampus harvested from wild type mice (Ate1
+/+; n=3), heterozygous mice
(Ate1
+/2;n=3 ) ,a n dAte1
2/2 mice (specifically, Ate1
flox/2;CaggCreER mice; n=3) mice 40 days after TM treatment. Standard deviations are indicated. (E)
Relativein vitroarginylation activity(cpm/reaction) intestis extracts from Ate1
+/+mice(n=3)andAte1
2/2mice(specifically,Ate1
flox/2;CaggCreER mice; n=3)
,130 days after TM treatment. Standard deviations are indicated.
doi:10.1371/journal.pone.0007757.g003
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tissue (WAT), on average only 16% of WAT in Ate1-containing
mice (Figs. 5D and 7A–C). These phenotypes are discussed below.
Spermatogenesis Defects and Infertility of Ate1-Deficient
Male Mice
The marking of Ate1
2 allele with NLS-b-galactosidase (bgal)
expressed from the PAte1 promoter revealed high levels of Ate1
expression in the neural tube and other specific, often sharply
delineated, regions of Ate1
+/2 embryos [10]. An earlier study
detected high levels of Ate1 expression in spermatogonia (stem
cells, located at the periphery of testis’ seminiferous tubules), and
possibly also in early meiotic spermatocytes of adult mice [26].
Male Ate1
2/2;CaggCreER mice that were produced by TM
treatment (Fig. 4C) were found to be infertile in matings with
Ate1-containing females, in contrast to identically TM-treated
Ate1-containing males (data not shown). XGal staining of testis
sections of NLS-bgal-marked Ate1
+/2 mice in the present work
(Fig. 6J) confirmed and extended the earlier evidence [26] for the
pattern of Ate1 expression in testis. Whereas the lumens of
seminiferous tubules in Ate1-containing testis were filled with
inward-pointing sperm tails, the lumens of tubules in Ate1-
deficient testis contained few sperm cells, in a disorganized
arrangement (Fig. 6F–I), in agreement with the observed infertility
of Ate1-deficient males.
To address the timing of requirement for Ate1 during
spermatogenesis, we mated wild-type females with Ate1
flox/2 males
that contained (instead of the CaggCreER gene) the PrpCreER gene
(line 28.8) [27] or the PrmCre gene [28]. PrpCreER expresses TM-
inducible CreER from the Prp promoter, whose activity in testis is
confined to spermatogonia and meiotic spermatocytes [27]. In
contrast, PrmCre expresses the (unconditionally active) Cre
recombinase from the protamine promoter, which is active at
later stages of spermatogenesis, in (haploid) round and elongating
Figure 4. Growth rate consequences of postnatal ablation of Ate1. (A) Weights of Ate1-containing (n=4; black curve) and Ate1-deficient
(n=2; red curve) mice from the same litter as a function of time after tamoxifen (TM) treatment. Weights were measured at weekly intervals. Vertical
bars indicate the ranges of measured weights. (B) Averaged growth curves for the indicated numbers of mice after TM treatment, plotted as a
percentage of their weight immediately before TM treatment. Red, black and blue curves: Ate1
2/2 (n=87), Ate1
+/+ (n=55), and Ate1
+/2 (n=66) mice.
Red arrow indicates the time (,21 days) after TM treatment by which ,15% of Ate1-deficient mice have died while the rest of them began to gain
weight. Note a slightly but clearly decreased weight of heterozygous (Ate1
+/2) mice (blue curve), in comparison to Ate1
+/+ mice (black curve) ,1 year
after TM treatment. Error bars indicate standard deviations (SD). (C) Typical appearance of Ate1
2/2 versus wt mice (a smaller, leaner Ate1
2/2 mouse)
,1 year after TM-mediated ablation of Ate1. (D) Mean body lengths (6 SD) (from tip-of-nose to base-of-tail) between pairs of Ate1
2/2 (red bar) and
Ate1
+/+ (black bar) mice. This comparison was derived from the data in Fig. 5C. Statistical analysis was performed using an unpaired t-test (p,0.08).
doi:10.1371/journal.pone.0007757.g004
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flox/2
males (PrpCreER-based and PrmCre-based) and wild-type females were
set up. 33% fewer litters and 50% fewer pups were produced with
Ate1
flox/2;PrpCreER males, in comparison to Ate1
flox/2;PrmCre males
(Table 1). (This substantial difference is expected to be even larger in a
setting where an expressed Cre does not require a second, TM-
mediated step for activation, as is the case with TM-independent Cre
expressed from the Prm promoter, but not with TM-inducible CreER,
expressed from the Prp promoter.) Nearly equal numbers of the
Ate1
flox (active) and Ate1
2 (inactive) alleles were present in the
heterozygous progeny of matings that involved Ate1
flox/2;PrmCre
males (13 versus 14 pups containing Ate1
flox versus Ate1
2 alleles,
respectively). In contrast and most revealingly, only one Ate1
2
(inactive) allele but 12 Ate1
flox (active) alleles were present in the
progenyofmatingsthatinvolvedAte1
flox/2;PrpCreERmales(Table1).
These findings suggest that the PrmCre-mediated inactivation of the
Figure 5. Comparison of organ sizes and other parameters of Ate1
2/2 versus Ate1
+/+ mice. (A) Averaged growth curves (total body weight
(TBW)) for Ate1
flox/2;CaggCreER mice versus control mice in the absence of TM treatments. A cohort of ‘‘control’’ mice contained Ate1
flox/+ mice (n=2);
Ate1
flox/2 mice (n=2); Ate1
+/+ mice (n=1) and Ate1
+/+;CaggCreER mice (n=1) from 1 month of age through 8 months. None of the mice were treated
with TM. Vertical bars indicate standard deviations. (B) Typical ‘‘kyphoid’’ posture of an Ate1-deficient mouse (see also the main text). (C) A plot of
body lengths (in cm from tip-of-nose to base-of tail) in individual sets of Ate1-containing (black diamonds) and Ate1-deficient (red boxes) siblingsa t
the indicated ages. Each pair of symbols, at a given age, represents a single pair of siblings. The black horizontal line indicates the averaged body
length of all Ate1-containing mice (n=14). The red horizontal line indicates the averaged body length of all Ate1-deficient mice (n=14).
(D) Comparison of tissue weights (as a percentage of total body weight (TBW)). Numbers in parentheses indicate the numbers of mice sampled and
averaged for each tissue (Ate1-containing and Ate1-deficient). Brain (n=43), liver (n=28), heart (n=17), kidney (n=17), spleen (n=16), white adipose
tissue (WAT; n=10), brown adipose tissue (BAT; n=10), pancreas (n=6), and testis (n=8) from Ate1-containing (black bars) and Ate1-deficient mice
(red bars). * = p,8610
215;* *=p ,5610
25; and *** = p,0.003. Statistical analysis was performed using an unpaired t-test. Standard deviations are
indicated.
doi:10.1371/journal.pone.0007757.g005
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PLoS ONE | www.plosone.org 7 November 2009 | Volume 4 | Issue 11 | e7757Figure 6. Brain, behavioral, and testis abnormalities of Ate1-deficient mice. (A) Enlarged brains of Ate1-deficient mice. Upper panel:
comparison of representative brains harvested from an Ate1
+/+ and an Ate1
2/2 mouse, respectively, 134 days after tamoxifen (TM) treatment. Lower
panel: brain weights expressed as percentages of total body weights in Ate1
+/+ (n=41) and Ate1
2/2 (n=40) mice. Horizontal bars and numbers
indicate mean values. (B) Wet (0.4053 g versus 0.4608 g) and dry (0.1022 g versus 0.1119 g) weight components of the total mean brain weights
(6SD) in Ate1
+/+ and Ate1
2/2 mice. (C) Total distance traveled (in meters), over 15 min, in an open field test among mice of different genotypes
belonging to the same litter, 44 days after TM-treatment. Bar 1, Ate1
flox/+;CaggCreER mouse. Bar 2, Ate1
+/+;CaggCreER mouse. Bar 3, Ate1
+/+ mouse. Bar
4, Ate1
flox/2;CaggCreER mouse that was converted to Ate1
2/2 by TM treatment. Blue and red bars denote Ate1-containing and Ate1-deficient mice,
respectively. (D) Same as in C but maximum lengths of single movements (in centimeters). (E) Same as in C but mean velocities (in cm/second) over
15 min. (F) Paraffin sections (4 mm) of testis showing cross-sections of seminiferous tubules in Ate1
+/+ testis stained with hematoxylin and eosin (1506
magnification). (G) Same as in F but Ate1
2/2 testis. Note that sperm tails in the lumens of Ate1
2/2 tubules are sparse in comparison to those in Ate1
+/+
testis. (H) Same as in F but at 6006magnification. (I) Same as in G but at 6006magnification. (J) XGal staining for bgal activity in a 10-mm section of
Ate1
+/2 testis in which one copy of Ate1 was replaced by an ORF encoding NLS-b-galactosidase and expressed from the PAte1 promoter (1006
magnification). (K) Immunoblotting analysis, using antibody to poly (ADP-ribose) polymerase (PARP), of testis extracts from an Ate1-containing
(Ate1
flox/2 (+/2)) and an Ate1-deficient (Ate1
flox/2;CaggCreER (2/2)) mouse 16 days after TM treatment. Note the loss of the full-length length 116
kDa PARP and the presence of the 85 kDa PARP fragment (lane2). An asterisk denotes a protein crossreacting with anti-PARP antibody.
doi:10.1371/journal.pone.0007757.g006
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flox allele, which occurs at a post-meiotic stage of spermatogen-
esis [28], takes place at a time when Ate1 is no longer essential for
production of viable sperm cells, thus accounting for high frequency of
the Ate1
2 allele in the progeny of matings that involve Ate1
flox/2;PrmCre
males. In contrast, the PrpCreER-mediated inactivation of the Ate1
flox
allele, which takes place in meiot i cs p e r m a t o c y t e s[ 2 7 ] ,c l e a r l y
discriminated against the transmission of the Ate1
2 allele, in
comparison to the Ate1
flox (active) allele, most likely because
spermatocytes that became Ate1-deficient before they became haploid
were sufficiently perturbed by the absence of arginylation to either
Figure 7. Loss of white adipose tissue (WAT), resistance to high fat diet-induced obesity, and ectopic Ucp1 in WAT of Ate1-deficient
mice. (A–C) Visceral fat content of Ate1-containing mice. Shown here are representative examples of Ate1-containing (Ate1
flox/+;CaggCreER) (A) and
Ate1
flox/2 (B)) and Ate1-deficient (Ate1
flox/2;CaggCreER (C)) mice 37 days after TM-treatment. Note the loss of both visceral fat (large white arrow in A
and B) and fat surrounding the kidney (small white arrows in A and B) in an Ate1-deficient mouse (C). (D) Hematoxylin/eosin staining of a 10-mm
section of white adipose tissue (WAT) harvested from an Ate1-containing mouse (TM-treated Ate1
flox/+;CaggCreER). The bar denotes 100 mm. (E) Same
as in D except that WAT was from an Ate1-deficient mouse (TM-treated Ate1
flox/2;CaggCreER). (F) Average weights of TM-treated Ate1-containing
(n=12; black curve) and Ate1-deficient (n=11; red curve) mice as a function of time after the beginning of ad libitum high-fat diet. Weights were
measured at weekly intervals for 10 weeks. Error bars indicate 6SD. (G) Comparisons, by immunoblotting, of Ucp1 protein levels in extracts from
brown adipose tissue (BAT) (lanes 1 and 2) and WAT (lanes 3 through 6) from Ate1
+/2 and Ate1
2/2 mice 46 days (lanes 1 and 2) or ,1 year (lanes 3–6)
after TM treatment. Specific genotypes were as follows (genotypes after TM treatment are indicated in parentheses here, and also on top of the gel):
lane 1, Ate1
flox/2 (+/2); lane 2, Ate1
flox/2;CaggCreER (2/2); lane 3, Ate1
flox/2;CaggCreER (2/2); lane 4, Ate1
flox/2 (+/2); lane 5, Ate1
flox/2;CaggCreER (2/2); lane
6, Ate1
flox/+;CaggCreER (+/2). Note abnormally high expression of Ucp1 in WAT of Ate1-deficient mice (lanes 3 and 5). An asterisk denotes a protein in WAT
that cross-reacts with anti-Ucp1 antibody. (H) RT-PCR analyses of leptin and Ucp1 mRNA levels in BAT (lanes 1–4) and WAT (lanes 5–8) of Ate1-containing
(denoted as ‘‘+/2’’; lanes2, 4, 6,and 8) and Ate1-deficient (denoted as‘‘2/2’ ’ ;l a ne s1 ,3 ,5 ,a n d7 )m i ce,1 year after TMtreatment.Specific genotypes:lanes
1a n d5 ,Ate1
flox/flox;CaggCreER (2/2); lanes 2 and 6, Ate1
flox/+;CaggCreER (+/2); lanes 3 and 5, Ate1
flox/flox;CaggCreER (2/2); lanes 4 and 8, Ate1
flox/2 (+/2). (I)
RT-PCR analyses of Ucp1and Ucp2 mRNA levels in BAT, liver, muscle, and WAT of an Ate1
flox/+ mouse (denoted as ‘‘+/2’’) and an Ate1
flox/2;CaggCreER mouse
(denoted as ‘‘2/2’’),1 year after TM treatment.
doi:10.1371/journal.pone.0007757.g007
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cells.
Previous work demonstrated a defective assembly of synapto-
nemal complexes and massive apoptosis of spermatocytes in
Ubr2
2/2 mice [26]. The Ate1 R-transferase acts upstream of Ubr2
and other Ub ligases of the N-end rule pathway (Fig. 1A). Given a
role of Ate1 in spermatogenesis demonstrated in the present study,
it is possible that the currently unknown N-end rule substrate(s)
whose degradation is in down-regulated in Ubr2
2/2 spermatocytes
is an Ate1 substrate. To assess the extent of apoptosis in Ate1-
deficient spermatocytes, we employed immunoblotting with
antibody to poly(ADP-ribose)-polymerase (PARP), which is
cleaved by caspases late in apoptosis. Anti-PARP antibody
detected the (expected) 116 kDa full-length PARP in extracts
from Ate1-containing mouse testis, but no 85-kDa PARP
fragment, a marker of apoptosis (Fig. 6K, lane 1) [29]. In contrast,
Ate1-deficient testis contained the 85-kDa fragment of PARP but
virtually no full-length PARP, indicating extensive apoptosis in the
absence of Ate1 (Fig. 6K, lane 2; cf. lane 1), in agreement with
cytological and Ate1
2/2 male-infertility data (Fig. 6F–I). The 85-
kDa PARP fragment is expected to bear N-terminal Gly [29],
which is not a substrate of the Ate1 R-transferase (Fig. 1A). Thus
the absence of the 85-kDa PARP fragment in Ate1-containing
testis (Fig. 6K, lane 1) signifies the lack of production of this
fragment by caspases, rather than its degradation by the
arginylation branch of the N-end rule pathway. Proteins that
require N-terminal arginylation for their degradation and that are
likely to be relevant to meiotic functions of Ate1 include Rec8
[30,31], a subunit of meiotic cohesin whose cleavage by separase is
expected to produce an Ate1 substrate, similarly to the cleavage of
Scc1/Rad21, the somatic counterpart of Rec8 (see Introduction).
Hyperkinesia, Seizures, and Enlarged Brains of
Ate1-Deficient Mice
Most of Ate1
2/2;CaggCreER mice (96 of 180) were strikingly
hyperactive (hyperkinetic) (Figs. 6C–E and 8A). Intact brains
harvested from Ate1-deficient mice appeared swollen, in compar-
ison to brains harvested, in parallel, from Ate1-containing siblings
(Fig. 6A). While the average brain weight, as a percentage of total
body weight (TBW), of Ate1-containing mice was 1.96%, that of
Ate1
2/2;CaggCreER mice was 3.09% (Fig. 6A). In addition, there
was a larger scatter of relative brain weights for Ate1-deficient
mice, in comparison to identically TM-treated Ate1-containing
controls. In particular, the brains of some Ate1-deficient mice
reached 5% of TBW (Fig. 6A). Histological patterns of NLS-bgal
[10] expressed from the PAte1 promoter in the brains of Ate1
+/2
mice (data not shown) were in agreement with in situ hybridization
data in the Allen Brain Atlas (http://www.brain-map.org/), in that
Ate1 was expressed at varying but significant levels throughout the
mouse brain, particularly in the hippocampus, dorsal thalamus,
and cerebellum. No Ate1 protein could be detected in brain
extracts of Ate1
2/2;CaggCreER mice, in contrast to extracts from
wild-type or Ate1
+/2 brains (Fig. 1C, D). The virtually null Ate1
state of the brain in Ate1
2/2;CaggCreER mice was also indicated by
a strong accumulation of Rgs4, a physiological substrate of Ate1
(see Introduction) (Fig. 1D).
We carried out cell proliferation assays with Ate1
2/2;CaggCreER
mice (and controls), using 5-ethynyl–29-deoxyuridine (EdU). In
examinations of EdU-labeled brain sections, we paid particular
attention to regions such as the hippocampus and the periven-
tricular zone of the lateral ventricles, where neurogenesis is known
to occur. However, no differences in EdU incorporation between
Ate1-deficient and Ate1-containing brains were observed (data not
shown), consistent with a brain edema (fluid accumulation) being a
significant cause of brain enlargement in Ate1-deficient mice. We
also determined the water content of freshly isolated brains, by
subtracting their ‘‘dry weights’’ (after freeze-drying) from their
total weights. The average water content and dry weight of control
(Ate1-containing) brains was 79.9% and 20.1%, respectively,
versus 80.5% and 19.5%, respectively (p,0.03), for Ate1-deficient
brains (Fig. 6B). Thus cerebral edema at least contributes to the
observed differences in brain weight between Ate1-deficient and
Ate1-containing mice. It remains to be determined whether an
edema (owing, e.g., to an osmotic imbalance or inflammation)
suffices to account for consistently observed Ate1-dependent
differences in brain weights (Fig. 6A, B).
There was also a 10-fold higher propensity for seizures among
Ate1-deficient mice. For example, during routine cage changes
and handling of mice, ,3.1% of Ate1-deficient mice (38 of 1,232)
versus ,0.3% of identically TM-treated Ate1-containing mice had
tonic-clonic seizures. The skulls of Ate1-deficient mice appeared to
be thinner, ‘‘softer’’ than the sculls of Ate1-containing mice.
Although MRI analyses did not reveal statistically significant
abnormalities in the shape or size of skulls in Ate1-deficient mice
(Fig. 8B, C), the MRI data did not preclude the possibility that
bone structure may be perturbed in the absence of Ate1. These
issues remain to be addressed.
The neurological/behavioral abnormalities of Ate1-deficient
mice included an enhanced startle response, a marker for
increased anxiety in rodents. Specifically, the latency between
stimulus and response (Tmax) for Ate1-deficient mice was between
54% and 76% of the average latency for Ate1-containing controls,
i.e., Ate1-deficient mice reacted significantly faster (Fig. 8D), thus
exhibiting an enhanced startle response. The open field test is used
to assess locomotor, exploratory and anxiety-like behavior in
rodents. This test revealed a remarkably hyperkinetic behavior of
Ate1-deficient mice (Figs. 6C–E and 8A), consistent with their
enhanced startled response (Fig. 8D). The initial test involved a 15-
min comparison of movements of Ate1-deficient mice versus Ate1-
containing siblings of the same litter. An Ate1-deficient mouse
traveled, during the test, a 3-fold greater distance than their
(identically TM-treated) Ate1-containing counterpart (175.71 m
versus 55.63 m, respectively) (Fig. 6C). The mean velocity of an
Ate1
2/2;CaggCreER mouse was 19.5 cm/sec, in comparison to
7.0 cm/sec for a wild-type (Ate1
+/+) mouse, 6.2 cm/sec for an
Ate1
+/+;CaggCreER mouse, and 5.5 cm/sec for an Ate1
flox/+;CaggC-
reER mouse (Fig. 6E).
Table 1. Genotypes of mice from matings of Ate1
+/+ females
with Ate1
flox/2 males containing testis-specific Cre transgenes.
Ate1
flox/2;PrmCre =
x wild type R
Ate1
flox/2;Prp28.8Cre = x
wild type R
# breeding pairs 3 3
# litters 6 4
Average litter size 7 5.25
total pups 42 21
# floxOFF 14 1
% floxOFF 33 4.7
# floxON 13 12
% floxON 31 57
Matings involving the Prp28.8 Cre strain occurred ,1 month following TM
treatment.
doi:10.1371/journal.pone.0007757.t001
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the open field test with three Ate1-deficient mice at 10, 26, 38,
and 82 days after TM treatment, in parallel with TM-treated
Ate1-containing (control) mice. At 10 days after TM treatment,
i.e., soon after the acquisition of the Ate1
2/2 genotype, the
differences between distances travelled by Ate1-deficient versus
Ate1-containing mice were small (Fig. 8A). However, by 26 days
after TM treatment, there was a statistically significant
difference between Ate1-deficient and Ate1-containing mice
in regard to their locomotor activity (Fig. 8A). By 82 days after
TM treatment, the locomotor activity of Ate1-deficient mice, in
conjunction with their elevated overall anxiety, increased so
much that the device in which the open field tests were
performed became nearly impractical, as Ate1-deficient mice
(in contrast to Ate-containing ones) kept jumping out of the
testing box.
Figure 8. Brain abnormalities and behavioral phenotypes of Ate1-deficient mice. (A) Ate1-deficient mice become hyperactive as a function
oftimeafterTM-mediatedablationofAte1.Totaldistance(incm)traveledover15 minintheopenfieldtestbox(2500 cm
2).Thistestwasrepeatedevery
,2 weeks after the end of TM treatment. The data for Ate1-containing mice (n=5; their genotypes were Ate1
flox/+, Ate1
flox/2, and Ate1
flox/+;CaggCreER)
and Ate1-deficient mice (n=3; Ate1
flox/2;CaggCreER) are indicated by black diamonds and red circles, respectively. The horizontal bars indicate mean
values. The average total distance traveled over 15 min for all Ate1-containing mice (n=37) was 4,870 cm. (B) Representative magnetic resonance
images showing equivalent horizontal planes of Ate1-containing (Ate1
flox/+;CaggCreER on the left, Ate1
flox/+ on the right) brains ,3 months after TM
treatment. The indicated average width of the skull (measured at the widest point from left to right in the same plane) of four Ate1-containing mice was
10.6 mm (60.89 mm). (C) Same as in B except with brains from Ate1-deficient (Ate1
flox/2;CaggCreER)m i c e,3 months after TM-treatment. The average
width of the skull (measured as in B) of four Ate1-deficient mice was 10.8 mm (60.38 mm). (D) Comparison of the response latency (Tmax; recorded in
msec) between Ate1-containing (n=3; black bars) and Ate1-deficient mice (n=3; red bars) to a 40-msec pulse of 120 dB (p120; p,0.3), a 40-msec pulse
of 120 dB preceded by a pre-pulse of 5 dB (pp5; p,0.09), or a 40-msec pulse of 120 dB preceded by a pre-pulse of 15 dB (pp15; p,0.01). Statistical
analysis was performed using an unpaired t-test.
doi:10.1371/journal.pone.0007757.g008
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Mice, and Their Resistance to Diet-Induced Obesity
To address the cause of a strikingly lower content of the
peritoneal white adipose tissue (WAT) in Ate1-deficient mice, on
average only 16% of WAT in Ate1-containing mice (Figs. 5D and
7A–C), we examined sections of intraperitoneal WAT. The average
diameter of WAT adipocytes from Ate1-deficient mice was ,30%
of the averagediameter of such cells in identicallyTM-treatedAte1-
containing mice (25.567.4 mm versus 76.2616.2 mm, respectively)
(Fig. 7D, E). Thus, at least the bulk of WAT decrease in Ate1-
deficient mice resulted from a decreased lipid content of individual
adipocytes, rather from an extensive loss of adipocytes. Similar
results were obtained with intrascapular brown adipose tissue (BAT)
(Fig. 9A, B). The leanness of Ate1-deficient mice was particularly
striking in view of their hyperphagy (see below).
We also asked whether the consistent difference in weight
between Ate1-deficient and Ate1-containing mice on a standard
ad libitum diet (Fig. 4A–C) could be reduced by an energy-rich,
high-fat diet (HFD). At the end of the resulting 10-week test, the
average weight of HFD-treated Ate1-containing mice was 152% of
their starting weight (40.0 g versus 26.3 g). In contrast, the average
weight of identically HFD-treated Ate1-deficient mice was only
122% (24.0 g versus 19.7 g) of their starting weight (Fig. 7F),
indicating their relative resistance to diet-induced obesity. Yet
Figure 9. Body temperature, amino acid utilization and other properties of Ate1
2/2 versus Ate1
+/+ mice. (A) Hematoxylin/eosin staining
(2006magnification) of a 10-mm section of brown adipose tissue (BAT) harvested from an Ate1-containing mouse (TM-treated Ate1
flox/+;CaggCreER).
The bar denotes 100 mm. (B) Same as in A except that BAT was from an Ate1-deficient mouse (TM-treated Ate1
flox/2;CaggCreER). (C) Relative
efficiencies of the import of
14C-amino acids and/or peptides from gastrointestinal tract in an Ate1-containing mouse (black bars; Ate1
flox/+;CaggCreER)
versus an Ate1-deficient mouse (red bars; Ate1
flox/2;CaggCreER) 26 days after TM treatment. Shown here are representative comparisons of the
retention of
14C (in cpm/gm) in the brains, livers, spleens, and kidneys 48 hr after gavage with a single bolus of
14C-labeled proteins (see Materials
and Methods). (D) Total
14C (cpm) in the feces produced by mice in C within the first 48 hr after gavage with a bolus of
14C-labeled proteins. (E)
Average core body temperatures of Ate1-containing (n=8; black circles) versus Ate1-deficient (n=11; red circles) mice during the first 3 weeks after
TM treatment, in comparison to average core body temperatures of Ate1-containing (n=54; black diamonds) versus Ate1-deficient (n=36; red
diamonds) mice beyond the first 3 weeks after TM treatment. (F) Core body temperature of individual Ate1-containing (black curves) and Ate1-
deficient (red curves) mice, recorded at 30-min intervals after placing mice in a room at 4uC. Mice were removed from the cold room after 6 hr or
when their core body temperature fell below 28uC.
doi:10.1371/journal.pone.0007757.g009
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initial loss of weight after TM treatment (Fig. 4A, B), was their
lower core body temperature, on average 35.1uC, in comparison
to identically TM-treated Ate1-containing control mice, whose
average core body temperature was 36.0uC during the same time,
in the absence of weight loss (Fig. 9E). After the early deaths of
,15% of Ate1
2/2;CaggCreER mice (Fig. 4A, B), the average
temperature of surviving mice (36.6uC) was not significantly
different from that of Ate1-containing control mice (36.7uC)
(Fig. 9E). As one would expect from their depletion of WAT
(Fig. 7A–C), Ate1-deficient mice were strongly hypersensitive to
cold (Fig. 9F).
Ucp1 is a proton carrier in the mitochondrial inner membrane
that mediates a partial uncoupling of oxidative phosphorylation
from ATP synthesis, an alteration that can increase heat
production and thereby regulate body temperature and energy
homeostasis. Although Ucp1 is normally expressed in BAT but not
in WAT, several mouse mutants other than Ate1
2/2 that are
resistant to diet-induced obesity have been shown to ectopically
express Ucp1 in WAT [32,33]. Using RT-PCR and immunoblot-
ting with anti-Ucp1 antibody, we found that the levels of Ucp1
mRNA and Ucp1 protein in BAT did not change significantly
between Ate1-deficient and Ate1-containing mice (Fig. 7G–I).
Remarkably, however, the levels of both Ucp1 mRNA and Ucp1
were strongly increased in WAT of Ate1-deficient mice (Fig. 7G–
I). A Ucp1-Ate1 connection revealed by these findings adds a new
dimension to the understanding of Ucp1 regulation ([32] and refs.
therein), and may also provide an experimental route to
identifying a relevant circuit that involves Ate1.
Increased Metabolic Rate in Ate1-Deficient Mice
During the week prior to TM treatment, Ate1
flox/2;CaggCreER
and control (Ate1
flox/+;CaggCreER) mice (at that point, both strains
contained Ate1) consumed 0.63 and 0.62 kcal of standard chow
per gram of body weight per day, respectively (Fig. 10C). Within a
week after TM treatment the now Ate1-deficient Ate1
2/2;CaggC-
reER mice increased their food consumption on average to 125%
of identically TM-treated Ate1-containing mice (Fig. 10C). This
pattern of significant hyperphagia of Ate1-deficient mice contin-
ued for the duration of this study, i.e., up to ,8 months, with
regular measurements for 6 weeks following TM treatment and
intermittent comparisons afterwards (Fig. 10C). Thus, despite their
initial decline of weight shortly after TM treatment and the early
death of ,15% of Ate1-deficient mice, and despite their
subsequent failure to gain, on average, more than ,63% and
,69% of the weights of Ate1
+/+
and Ate1
+/2 mice, respectively, the
Ate1-deficient mice consumed significantly more food than their
Ate1-containing counterparts (Fig. 10C). To address their patterns
of glucose utilization, we fasted these mice for 16 hr and measured
blood glucose before after administering a 50-mg (0.2 ml) bolus of
glucose by gavage. The kinetics of rise and fall of blood glucose
levels under these conditions was similar for Ate1-deficient and
Ate1-containing mice (Fig. 10A). Ate1-deficient mice had lower
fasting glucose levels than Ate1-containing mice (88.6 mg/dl
versus 125.3 mg/dl, respectively; p,0.04), and also lower glucose
levels 6 hr after administration of glucose (80.9 mg/dl versus
109.7 mg/dl, respectively; p,0.04), consistent with the (expected)
higher energy expenditure of Ate1-deficient mice, and suggesting
normal sensitivity of these mice to insulin (Fig. 10B). There were
no other significant differences in blood composition (as well as
urine composition) between Ate1-containing and Ate1-deficient
mice (Tables 2 and 3).
To measure metabolic rate, we employed indirect calorimetry
(see Materials and Methods), determining O2 consumption and
CO2 production by mice under resting conditions. The metabolic
rate (resting metabolic rate, RMR) of Ate1-deficient mice was
indeed higher than normal: they consumed on average 46.12 ml
of O2 per kg per min, versus 29.3 ml of O2 per kg per min for
Ate1-containing mice (Fig. 10E). In contrast, the respiratory
exchange ratio, RER (the ratio of CO2 eliminated from the lungs
to O2 taken into the lungs), a parameter that depends on a
preferred source of fuel (e.g., carbohydrates versus fat), was similar
for Ate1-deficient and Ate1-containing mice: 0.75 and 0.76,
respectively (Fig. 10F).
The S. cerevisiae N-end rule pathway regulates the import of
short peptides through the conditional degradation of Cup9, the
import’s repressor [34]. It is likely (but remains to be verified) that
the N-end rule pathway regulates the transmembrane traffic of
peptides in mammals as well. To address the possibility that
significantly lower weights (despite hyperphagia) of Ate1-deficient
mice might stem, at least in part, from an impaired ability to
import peptides and/or amino acids from their gastrointestinal
(GI) tract, we labeled E. coli with a mixture of
14C-amino acids
and isolated a
14C-protein fraction that was essentially free of
nucleic acids, fatty acids, lipids and carbohydrates (see Materials
and Methods). Ate1-deficient and Ate1-containing mice were
gavaged with a bolus of this
14C-protein preparation, followed by
measurements of
14C in several organs of these mice (and in their
feces) as a function of time post-gavage. Ate1-deficient mice passed
less
14C in feces than Ate1-containing mice (Fig. 9D). Moreover,
Ate1-deficient mice accumulated more of
14C in their brains,
livers, spleens, kidneys and hearts than Ate1-containing mice
(Figs. 9C and 10D). Irrespective of mechanistic causes involved
(they remain to be understood), higher than wild-type levels of
protein-derived
14C delivered to tissues of Ate1-deficient mice
indicated the absence of significant defects in their transport of
peptides and/or amino acids from GI tract.
Given the metabolic and behavioral abnormalities of Ate1-
deficient mice (Figs. 6C–E, 8A, D and 10E, F), we also examined
them for expression of neuropeptides. As we would be interested,
at present, only in strong differences, a semiquantitative RT-PCR
was employed. Using total RNA from hypothalami of Ate1-
deficient versus Ate1-containing mice, we found no consistent
differences between these mice in regard to the levels of
hypothalamic mRNAs that encoded the agouti-related protein
(AgRP) and the neural peptide Y (NPY) (Fig. 10G). Strikingly,
however, there was a consistent and strong decrease of expression,
in Ate1-deficient mice, of mRNA encoding proopiomelanocortin
(POMC) (Fig. 10G). POMC is a precursor of several neurohor-
mones with broad systemic and brain-specific functions ([35] and
refs. therein). These functions include a role in melanocyte
regulation (a process that is likely to be perturbed in Ate1-deficient
mice; see above) and a down-regulation of food intake (the
observed deficiency in POMC is consistent with hyperphagia of
Ate1-deficient mice (Fig. 10C, G)). Similarly to a connection
between Ate1 and the Ucp1 uncoupling protein (Fig. 7G–I), our
finding of a link between N-terminal arginylation and the
expression of POMC is likely to provide an experimental route
to identifying the relevant Ate1-dependent circuit.
Discussion
A cell is alive owing to a cell-wide dynamic network of
structurally or functionally interacting biopolymers. Some parts of
this network can be sufficiently insulated, through their design, to
be considered, in the first approximation, as distinct circuits. The
N-end rule pathway is one such circuit. Its enzymes receive as
their input specific degron-bearing proteins and convert them,
Ablation of R-Transferase
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cessive degradation, into an output of proteolysis-derived short
peptides (Fig. 1A). The rate and selectivity of the proteasome-
mediated protein degradation by the N-end rule pathway are
modulated by physiological effectors, including specific phospho-
kinases, short peptides, redox, heme and nitric oxide (see
Introduction). Some of N-end rule substrates are produced by
proteases that include MetAPs, separases, caspases and calpains.
These and other nonprocessive proteases, which function as
upstream components of the N-end rule pathway, have in
common their ability to convert, through a cleavage, a pro-N-
degron into an N-degron.
Figure 10. Energy balance and metabolic rate in Ate1-deficient mice. (A) Glucose tolerance test. Glucose concentration (mg/dL) in whole
blood of Ate1-containing mice (n=15; black curve) and Ate1-deficient mice (n=11; red curve), at different times after a bolus of glucose by gavage,
following a 16-hr fast. Glucose was administered at time zero. Error bars indicate 6SD. (B) Fasting blood glucose levels. Average blood glucose levels
(mg/dL) in Ate1-containing mice (n=15; black bar) and Ate1-deficient mice (n=11; red bar), with measurements shortly before glucose gavage (after
a 16-hr fast) and 6 hr after the gavage in A. Standard deviations are indicated. Statistical analysis was performed using an unpaired t-test (p,0.04). (C)
Average daily energy consumption (kcal/gm of body weight) for Ate1-containing mice (n=5; black curve) and Ate1-deficient mice (n=3; red curve),
with measurements from 1 week prior to tamoxifen (TM) treatment. Vertical arrow indicates the beginning of a 5-day TM treatment. Error bars
indicate 6SD. (D) Relative efficiencies of the import of
14C-amino acids and
14C-peptides from gastrointestinal tract in Ate1-containing mice (black
bars) versus Ate1-deficient mice (red bars). Shown here are representative comparisons of the retention of
14C (in cpm/gm) in the brains, livers,
spleens, kidneys, and hearts of indicated mice 16 days after gavage with a single bolus of
14C-labeled proteins (see Materials and Methods). Mice were
gavaged 26 days after TM treatment. (E) Comparison of resting metabolic rate (RMR) (measured in O2 (ml) consumed per kg of body weight per min)
for Ate1-containing mice (n=6; black bar) versus Ate1-deficient mice (n=6; red bar). Standard deviations are indicated in E and F. Statistical analysis
was performed using an unpaired t-test (p,0.008). (F) Comparison of the respiratory exchange ratio (RER), measured as CO2 (in ml) per ml of O2, for
Ate1-containing mice (n=6; black bar) and Ate1-deficient mice (n=6; red bar) mice. No statistically significant difference in RER was observed. (G) RT-
PCR analyses of AgRP, MCH, HPY, and POMC mRNA levels in the hypothalami of TM-treated Ate1-containing mice (Sets 1 and 4) versus Ate1-deficient
mice (Sets 2 and 3). Set 1, Ate1
flox/flox (+/+); Set 2, Ate1
flox/flox;CaggCreER (2/2); Set 3, Ate1
flox/flox;CaggCreER (2/2); Set 4, Ate1
flox/+;CaggCreER (+/2). In
sets 1 and 2, hypothalami were isolated 93 days after TM treatment. In sets 3 and 4 hypothalami were isolated ,1 year after TM treatment. Sloping
triangles indicate decreasing inputs (by 2-fold) of total RNA.
doi:10.1371/journal.pone.0007757.g010
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Ate1 R-transferase (Fig. 1A) by making possible a postnatal
inactivation of mouse Ate1. (Unconditional deletion of Ate1 results
in embryonic lethality [10].) Described and discussed in Results is
a large set of defects, some of them quite striking, in juvenile and
adult mice upon the postnatal inactivation of Ate1 and the resulting
loss of N-terminal arginylation (Figs. 1C, D). The initial
abnormality is a rapid decrease of body weight and early death
of ,15% of Ate1-deficient mice, with surviving mice attaining,
gradually, only ,70% of the weight of wild-type mice identically
treated with tamoxifen (TM) (Fig. 4A–C). Both ‘‘partial’’ lethality
and the transiency of acute crisis, over ,3 weeks after TM
treatment (red arrow in Fig. 4B), remain to be understood in
molecular terms. This crisis and subsequent failure to thrive occur
despite higher than normal food intake by Ate1-deficient mice
(Fig. 10C). These mice contain little or no visceral fat (Figs. 5D and
7A–E), and exhibit an increased metabolic rate (Fig. 10E),
resistance to diet-induced obesity (Fig. 7F), enlarged brains
(Figs. 5D and 6A), kyphosis (Fig. 5B), a striking hyperkinesia
(Figs. 6C–E and 8A), and male sterility (Fig. 6F–K).
Owing to current constraints of the Cre-lox technology ([25]
and refs. therein), the extent of Ate1 inactivation, while nearly
100% in some mouse tissues, was variable in others. The TM-
induced Ate1
2/2;CaggCreER mouse strains are thus mosaics of
Ate1
flox/2 and Ate1
2/2 cells, where Ate1
2/2 cells are a great
majority in most organs, such as the brain, but even there do not
reach 100% of all cells (see Results). The initial weight loss upon
the TM-induced conversion of Ate1
flox/2 mice to Ate1
2/2 mice was
accompanied by death of ,15% of Ate1
2/2 mice (Fig. 4A, B).
Such a ‘‘partially’’ lethal phenotype suggests that an adult-onset
Ate1
2/2 genotype in all cells (as distinguished from most cells) of a
mouse might be incompatible with viability, similarly to the
Table 2. Serum analyses.
Ate1-deficient Ate1-containing
Mean StDev Mean StDev Units normal range
Glucose 153.3 41.9 182.6 73.3 mg/dl 62–175
BUN 26.0 3.8 22.0 8.0 mg/dl 12–28
Creatinine 0.4 0.1 0.4 0.1 mg/dl 0.3–1.0
Sodium 158.0 2.8 129.8 62.3
Potassium 8.5 1.2 6.7 2.8
NA/K ratio 18.8 2.4 17.1 7.2
Chloride 112.8 3.4 91.9 43.4
CO2 21.5 2.8 20.8 9.1
Anion gap 32.3 1.9 24.3 11.6
Calcium 9.3 0.4 8.1 3.4 mg/dl 3.2–8.5
Phosphorus 10.5 2.8 8.6 3.8 mg/dl 2.3–9.2
Osm, Calc 328.0 6.6 270.9 129.6
TP 5.2 0.4 4.5 1.8 g/dl 3.5–7.2
Albumin 3.1 0.3 2.7 1.1 g/dl 2.5–4.8
Globulin 2.0 0.1 1.8 0.7 g/dl 0.6
Albumin/Globulin 1.5 0.1 1.3 0.5 4.1–8
Bilirubin 0.2 0.1 0.1 0.0 mg/dl 0.1–0.9
AP 102.3 41.6 113.7 48.0 U/L ,70
gamma gt 0.0 0.0 0.0 0.0 U/L
ALT 57.0 14.4 39.5 11.5 U/L ,60
AST 409* 286.5 199.2 83.9 U/L ,100
Cholesterol 70.1 4.0 71.5 31.8 mg/dl 26–82 (,1.5 mmol/L)
T4 2.7 0.9 2.4 0.8 ng/dl
T3 54.3 7.4 50.9 19.7 mg/dl
*Ate1-deficient mice with more severe phenotypes tended to have higher AST levels.
doi:10.1371/journal.pone.0007757.t002
Table 3. Urinalysis.
- Ate1-deficient Ate1-containing Units
Glucose neg neg mg/dL
Bilirubin neg/small neg/small
Ketone neg neg mg/dL
Specific Gravity 1.03 1.02
Blood neg neg
pH 6.2* 7.1
Protein 100 100 mg/dL
Urobilinogen 0.2 0.2 mg/dL
Nitrite neg neg
Leukocytes neg neg
*Ate1-deficient mice had a significantly lower urine pH.
doi:10.1371/journal.pone.0007757.t003
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2/2 mice. Thus,
paradoxically, the discovery, in the present study, of specific
Ate1-linked defects in adult mice might have been made possible
by incomplete penetrance of the Cre-induced conversion of Ate1
flox
to the Ate1
2 allele.
The set of definitively identified mammalian N-end rule
substrates that involve N-terminal arginylation consists, at present,
of fewer than 10 proteins. They subserve different functions, from
chromosome segregation to control of apoptosis and regulation of
G proteins (see Introduction). This set is the tip of the iceberg, as
several considerations [2], in addition to our findings above,
strongly suggest a larger number of physiological Ate1 substrates.
Given this complexity, the specific and often striking phenotypes of
Ate1-deficient mice that were discovered in the present work will
be of major assistance in deciphering the underlying Ate1 circuits.
Methods
Animal Care and Treatments
All animal care and procedures in the present study were
conducted according to the relevant NIH guidelines, and were
approved (Protocol #1328) by the Institutional Animal Care and
Use Committee, the Office of Laboratory Animal Research
(OLAR) at the California Institute of Technology, where the entire
present study was carried out. Mice were housed at ,22uC, at a
pathogen-free (barrier) facility, using a 12 hr light/12 hr dark
cycle, with Laboratory Rodent Diet 5001 (PMI International,
Richmond, IN) ad libitum. Mice aged between 3 and 8 weeks were
treated with tamoxifen (TM) (Sigma) (2 mg in 0.2 ml sesame oil)
by daily intraperitoneal (IP) injections over 5 days. Mice were
weighed weekly, starting 3 days before the first TM treatment. For
a high-fat diet (HFD) study, mice were fed ad libitum a diet
containing 35.5% fat (BioServe, Frenchtown, NJ), and were
weighed weekly.
Construction of Ate1
flox/2;CaggCreER Mouse Strains
Mouse genomic DNA encoding Ate1 was isolated from a BAC
library [10]. Two pBluescript-based plasmids were used to
construct the targeting vector. In one insert, a ,12 kb HindIII
fragment contained Ate1 exons 1a, 1b, 2, and 3 as well as ,1.9 kb
of DNA 39 of exon 3 (ending just before exon 4). In the other
insert, a ,2.9 kb fragment contained Ate1 exons 4 and 5. The
entire ,12 kb HindIII fragment and a part of the ,2.9 kb
fragment were modified as described below and assembled into a
final ,22.5 kb targeting vector consisting of the following parts
(Fig. 2C): (i) pBR322 backbone (New England Biolabs, Ipswich,
MA); (ii)a,6.3 kb ‘‘long arm’’ of Ate1 homology containing the
Ate1 exon 1a, the bidirectional PAte1 promoter [14], and exon 1b;
(iii) A single loxP site ,300 bp upstream of Ate1 exon 2; (iv)a
,2 kb fragment that contains, 50 bp downstream of Ate1 exon 4,
a ‘‘floxed’’ Hph (hygromycin) antibiotic-resistance marker, ex-
pressed from the PPGK promoter [36]; (v)a,1.2 kb ‘‘short arm’’ of
Ate1 homology that spans most of the intron between exons 4 and
5; (vi) a gene encoding HSV-TK (herpes simplex virus thymidine
kinase), expressed from the PPGK promoter. The targeting vector
was linearized with BamHI and electroporated into CJ7
embryonic stem (ES) cells (a gift from Dr. Thomas Gridley,
formerly of Jackson Laboratories, Bar Harbor, ME). ES cells were
grown in DMEM supplemented with 15% fetal bovine serum
(FBS), 0.1 mM non-essential amino acids, 0.1 mM b-mercapto-
ethanol, 2 mM glutamine, 100 U/ml penicillin, 0.1 mg/ml
streptomycin, 1 mM pyruvate, and 1,000 U/ml leukemia inhib-
itory factor (LIF) [37], using a feeder layer of hygromycin-resistant
mouse primary fibroblasts that had been treated with 10 mg/ml
mitomycin C for 3 hr at 37uC. Selection with hygromycin (at
0.2 mg/ml) and 1-(29-deoxy, 29-fluoro-b-D-arabinofuranosyl)-5-
iodouracil (FIAU; at 0.4 mM) was started 24 hr after electropo-
ration. Correctly targeted ES cell clones that contained ‘‘tri-loxed’’
Ate1 allele (Figs. 2C, D) were identified using Southern
hybridization and PCR. Southern DNA probes and positions of
primers for PCR are indicated in Fig. 2.
Twocorrectlytargeted,independentlyproduced EScelllinesthat
had apparently normal karyotypes were injected into 3.5-days-
postcoitum C57BL/6J blastocysts and implanted into pseudopreg-
nant females. The resulting male chimeric offspring were mated
with C57BL/6J females. In some of the progeny, ‘‘floxed’’ ES cells
became a part of germ line. Standard mating techniques [36,38]
were then used to produce, initially, mouse strains that contained a
‘‘tri-lox’’ Ate1 configuration, in that they also contained the floxed
positive-selection PPGK-hph cassette (Fig. 2D). This DNA segment
was removed by mating Ate1-tri-lox heterozygotes with EIIa-Cre
mice that expressed Cre recombinase only in early, pre-implanta-
tion blastocysts [39,40,41]. Owing to the presence of three loxP sites
at the initial floxed Ate1 locus, F1 progeny from this cross were
mosaic, i.e., their tissues, including germ line, contained varying
configurations of retained loxP sites, depending on specific patterns
of Cre-mediated recombination (Fig. 2A–F). To isolate a mouse
strain with the desired configuration of (retained) loxP sites (Fig. 2E),
the above F1 mosaic mice were mated to wild-type C57BL/6 mice.
This produced, among other progeny, a strain that lacked the PPGK-
Hph cassette and had the desired Ate1
flox/+ genotype, in the (mixed)
C75BL/6J-129SvEv background.
Through the use of appropriate mating pairs, with genotyping of
resulting progeny, we produced Ate1
flox/2;CaggCreER mice as well as
Ate1
flox/flox;CaggCreER mice (Fig. 2). The former strain harbored one
unconditionally null Ate1
2 allele (derived, through matings, from the
previously constructed unconditional heterozygous Ate1
+/2 mice [10])
and one ‘‘floxed’’, conditionally active Ate1
flox allele that could be made
null in the presence of active Cre recombinase. In the latter strain
(Ate1
flox/flox;CaggCreER), both copies of Ate1 were Ate1
flox.T h e s em o u s e
strains also contained the CaggCreER gene, expressed from the
ubiquitously active chimeric Cagg promoter (Fig. 2E) [25]. CaggCreER
encoded CreER, a fusion between the phage P1 Cre recombinase and
a derivative of the mouse estrogen receptor ligand binding domain.
CreER was functionally inactive (sequestered in the cytosol) but could
be activated by intraperitoneal (IP) injection of tamoxifen (TM) [25].
To produce Ate1
flox/2;CaggCreER mice, we mated Ate1
flox/+ mice with
Ate1
+/2;CaggCreER mice (the latter were generated by mating Ate1
+/2
with Ate1
+/+;CaggCreER mice). To produce Ate1
flox/flox;CaggCreER mice,
we mated Ate1
flox/+ mice with Ate1
flox/+;CaggCreER mice (the latter were
generated by mating Ate1
flox/+ mice with Ate1
+/+;CaggCreER mice). In
the notations here and elsewhere in the paper, ‘‘flox-on’’ indicates a
configuration depicted in Fig. 2E (the functionally active Ate1
flox allele),
whereas ‘‘flox-off’’ indicates a configuration depicted in Fig. 2F (the
null Ate1
2 allele).
Southern Hybridization and PCR
Total genomic DNA was isolated from ES cells by washing them
twice with phosphate-buffered saline PBS, followed by an overnight
incubation at 50uC in 10 mM EDTA, 10 mM NaCl, 0.5%
Sarcosyl,10 mM Tris-HCl (pH 7.5) containing Proteinase K at
0.2 mg/ml. Thereafter an equal volume of 75 mM NaCl in 100%
ethanol was added. Precipitated genomic DNA was then gently
washed twice with 70% ethanol and resuspended in T10E0.1 buffer
(10 mM Tris (pH 8.0), 0.1 mM EDTA). Total genomic DNA was
isolated from mouse tails or other tissues by overnight incubation at
55uC, with constant rotation, in 5 mM EDTA, 0.2 M NaCl, 0.3%
SDS, 0.1 M Tris (pH 8.5) containing Proteinase K at 0.4 mg/ml.
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mixture was gently inverted several times. Genomic DNA was then
precipitated, and washed twice, with 70% ethanol, followed by a
gentle resuspension in T10E0.1 buffer.
Southern hybridization was performed as described [42], with
a
32P-labeled mouse DNA probes that was produced by PCR
using the following primers: CB108F and CB107R (Table 2) to
amplify a 219 bp genomic fragment containing Ate1exon 5 (probe
D, external probe); CB23 and CB24 (Table 4) to amplify a 929 bp
genomic fragment that was a part of the long arm of the targeting
vector (Probe A, internal probe) (Fig. 2). DNA probes were
labeled with
32P-labeled using the Rediprime-II Random Prime
Labeling System (Amersham Biosciences, Piscataway, NJ) ac-
cording to the manufacturer’s protocol. Hybridization with Probe
A was carried out overnight at 57uCi nE x p r e s s H y bs o l u t i o n
(Clontech). The membrane was then washed once for 10 min at
room temperature (RT) in 2xSSC/0.1% SDS, once for 30 min at
55uC in 2xSSC/0.1% SDS, once for 30 minutes at 58uCi n
0.5xSSC/0.1% SDS, and once for 30 minutes at 65uCi n
0.1xSSC/0.1% SDS, followed by autoradiography. (1xSSC is
0.15 M NaCl, 15 mM Na-citrate, pH 7.4.) Hybridization with
Probe D was carried out overnight at 55uCi nE x p r e s s H y b
solution (Clontech). The membrane was then washed once for
1 0m i na tR Ti n2 x S S C / 0 . 1 %S D S ,o n c ef o r3 0m i na t5 5 uCi n
2xSSC/0.1% SDS, and once for 30 min at 58uC in 1xSSC/0.1%
SDS, followed by autoradiography.
Genotyping of Mouse Strains
PCR-based genotyping was carried out with total genomic
DNA isolated from various mouse tissues. Routine genotyping was
performed using DNA from mouse tails. Specific Ate1 alleles and
transgenes encoding specific derivatives of Cre were identified as
Table 4. PCR primers used in the present study.
Name Nucleotide sequence (59 to 39)U s e
CB23 ACTTTACAGTTGCTAGATAAGC for PCR of Southern Probe A
CB24 AGCAGGTTACTTGTCCAGTC for PCR of Southern Probe A
CB107R AATTCTTTAGACCCTTCTTTGTTT for PCR of Southern Probe D
CB108F TGTCAATAATGCAGCTGATGATGGGCTTTCATTGTCTTCTCATTCTTAGATGAGCCCATGGATTCTAC for PCR of Southern Probe D
CB156F CAA GCAG GGG AAG GAG GC PCR detection ATE1-floxON
CB157R TTC AGG AGT TAG CCA TTG CC PCR detection ATE1-floxON and ATE1-floxOFF
AK49 GGT ATT TGC TGC CGT CCT TTG GTG GT PCR detection of ATE1-null
YT641 CTG TTC CAC ATA CAC TTC ATT CTC AG PCR detection of ATE1-null
AK83-Cbfix CTG GAG ACA AAG CCC CAG CCA GAC PCR detection of ATE1-null
Cre-1 GTT CGC AAG AAC CTG ATG GAC A PCR detection of Cre gene
Cre-2 CTA GAG CCT GTT TTG CAC GTT C PCR detection of Cre gene
CB159R AC TGT AGA ATC CAT GGG CTC PCR detection wild type ATE1
CB160F ACA GCA TAA GTG AGA CAC TCA PCR detection wild type ATE1
CB110F GTT TGT GTC ACC ACT CCT ACC PCR detection ATE1-floxOFF
oIMR0042 CTA GGC CAC AGA ATT GAA AGA TCT PCR detection IL-2 control
oIMR0043 GTA GGT GGA AAT TCT AGC ATC ATC C PCR detection IL-2 control
AgRP-for GCGGAGGTGCTAGATCCA RT-PCR
AgRP-rev AGGACTCGTGCAGCCTTA RT-PCR
NPY-for CTCCGCTCTGCGACACTAC RT-PCR
NPY-rev AATCAGTGTCTCAGGGCT RT-PCR
POMC-for ACCTCACCACGGAGAGCA RT-PCR
POMC-rev GCGAGAGGTCGAGTTTGC RT-PCR
MCH-for ATTCAAAGAACACAGGCTCCAAAC RT-PCR
MCH-rev CGGATCCTTTCAGAGCAAGGTA RT-PCR
cyclophilin-for GGTGGAGAGCACCAAGACAGA RT-PCR
Cyclophilin-rev GCCGGAGTCGACAATGATG RT-PCR
Ucp2-59 GGGGCGGCCGCATGGTTGGTTTCAAGGCCAC RT-PCR
Ucp2-39 GGGGCGGCCGCTCAGAAAGGTGCCTCCCGAG RT-PCR
Actb-59 ATGGATGACGATATCGCTGCG RT-PCR
Actb-39 GAAGCTGTAGCCACGCTCGG RT-PCR
Leptin-59 GGGGCGGCCGCATGTGCTGGAGACCCCTGTG RT-PCR
Leptin-39 GGGGCGGCCGCTCAGCATTCAGGGCTAACAT RT-PCR
Ucp1-59 GGGGCGGCCGCATGGTGAACCCGACAACTTC RT-PCR
Ucp1-39 GGGGCGGCCGCTTATGTGGTACAATCCACTG RT-PCR
doi:10.1371/journal.pone.0007757.t004
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(Table 4) was employed to produce and detect a 512 bp fragment of
the Ate1
flox (‘‘floxON’’, active) allele as well as a 472 bp fragment of the
wild-type Ate1
+ allele. A four-primer PCR using the CB110F,
CB157R, OIMR0042, and OIM0043 primers Z (Table 4) was
employed to produce and detect a 470 bp fragment of the Ate1
flox-
derived Ate1
2 allele (‘‘floxOFF’’) as well as a (control) 324 bp fragment
of the Il-2 gene. A three-primer PCR using the AK49, YT641, and
AK83-CBfix (Table 4) was employed to detect both a 300 bp
fragment of the unconditional Ate1
2allele [10] and a 560-bp fragment
of the wild-type Ate1
+ allele. A four-primer PCR using the Cre-1, Cre-
2, CB159R, and CB160F primers (Table 4) was employed to detect
both a 320 bp fragment of the CaggCreER transgene as well as a
1,060 bp fragment of the wild-type Ate1
+ allele. All PCR reactions
except for those to detect the CaggCreER transgene were carried out
using HotStar Taq DNA polymerase, standard buffer conditions
(Qiagen, Valencia, CA), 35 cycles of template denaturation for 30
seconds at 95uC, followed by primer annealing for 30 seconds at 60uC
and primer extension for 1 minute at 72uC. PCR reactions for
detecting CaggCreER were carried out using 30 cycles of template
denaturation for 30 seconds at 95uC, followed by primer annealing for
30 seconds at 58uC and primer extension for 45 seconds at 72uC.
Northern and RT-PCR Analyses of RNA
Total RNA was isolated from various mouse tissues using the
RNeasy Protect Mini Kit (Qiagen). Tissue disruption and
homogenization were done in Buffer RLT and the MP FastPrep-
24 instrument with Lysing Matrix D (MP Biomedicals, Solon, OH)
for 2 runs at 6.5 m/s. First-strand cDNA was primed with oligo-dT
using the SuperScript III First-Strand Synthesis System (Invitrogen,
Carlsbad, CA) and PCR was carried out using primers cited in
legends to the corresponding figures and in Table 4.
Tissue Extracts and Immunoblotting
Various mouse tissues were harvested and lysed in ‘‘Tissue Lysis
Buffer’’ (10% glycerol, 0.05% NP40, 0.15 M NaCl, 2 mM EDTA,
1 mM dithiothreitol (DTT) 1 mM phenylmethylsulfonyl fluoride
PMSF 50 mM HEPES, pH 7.5) plus freshly dissolved ‘‘Complete
EDTA-FreeProtease Inhibitors’’(Roche), using theMPFastPrep-24
instrument and Lysing Matrix D (MP Biomedicals, with 2 or 3 runs
at 6.5 m/s for 25 sec each, and with 5-min incubations on ice
betweentheruns.Thelysateswerecentrifugedat10,000gfor20 min
at 4uC. The supernatants were fractionated by SDS-12.5% PAGE,
transferred to Immobilon-P PVDF membranes (Millipore, Billerica,
MA),andanalyzedbyimmunoblotting(IB)withantibodiesindicated
in specific figures. Immunoblots were visualized using SuperSignal
West Pico or SuperSignal West Dura reagents (Thermo Scientific,
Rockford, IL) according to the manufacturer’s instructions.
Other Analyses of Mouse Tissues
Specific mouse tissues were dissected immediately after
euthanasia by CO2 inhalation. The tissues washed with PBS,
blotted dry on Kimwipes, and weighed (wet). For dry-weight
measurements, mouse brains were dissected intact, washed in PBS,
blotted dry on Kimwipes, weighed wet, then incubated overnight
in acetone. After acetone incubation, individual brains were
lyophilized until their (dry) weight no longer decreased.
For routine histological examinations, tissues or organs were fixed
in Bouin’s solution or in 4% formaldehyde, using standard
procedures [37]. Fixed samples were embedded in paraffin,
sectioned, and stained with hematoxylin and eosin. To stain for
LacZ (NLS-bgal), dissected tissues or organs were fixed in LacZfix
(0.2%glutaraldehyde,5 mMEGTA,0.1 MMgCl2inPBS(pH 7.3))
for 4 hr, rinsed twice with PBS, dehydrated overnight at 4uC in 30%
sucrose, 2 mM MgCl2 in PBS, and embedded and frozen in Tissue-
Tek O.C.T. Compound (Sakura Finetek USA, Inc. Torrance, CA).
Cryosections (prepared using a Tissue Tek Microtome/Cryostat
model 4553) were mounted onto glass slides, fixed in LacZfix for
10 min at RT, washed 3 times in LacZWash (0.02% NP40, 01%
Na-deoxycholate, 2 mM MgCl2 in PBS), and stained overnight at
37uCwith LacZstain(LacZWashcontaining1 mg/mlXGal,5 mM
K4Fe(CN)6 and 5 mM K3Fe(CN)6). Stained sections were washed
with PBS and mounted with Permount for light microscopy.
Apoptosis was assessed by TUNEL, a nuclear DNA fragmentation
assay, using a TUNEL kit (Roche, Indianapolis, IN), fluorescein-
dUTP, and manufacturer’s instructions. Cell proliferation was
assayed using the Click-It Edu Cell Proliferation kit (Invitrogen).
In Vitro Arginylation Assay
The arginyl-transferase (R-transferase) reaction (50 ml) con-
tained extracts for a specific mouse tissue (2.5 mg of total protein
per ml), a-lactalbumin (arginylation reporter [14]) (0.5 mg/ml),
total E. coli tRNA (0.6 mg/ml) (Sigma), total E. coli aminoacyl-
tRNA synthetases (800 U/ml) (Sigma), 5 mM MG132 (protea-
some inhibitor) (Sigma), 1 mM ATP, 30 mM KCl, 2 mM MgCl2,
2m M b-mercaptoethanol, 10 mM Tris-HCl (pH 8.0) and
0.3 mM
3H-arginine (PerkinElmer, NEN Radiochemicals, Wal-
tham, MA). The reaction mixture was incubated for 30 min at
37uC and deposited onto GF/C filter disks (GE-Healthcare,
Pittsburg, PA). The filters were thereafter incubated for 10 min in
10% cold CCl3COOH, followed by 10 min in 5% CCl3COOH at
95uC. The filters were then washed in 5% CCl3COOH 3 times at
RT, followed by a single ether:ethanol (1:1) wash, two ether
washes, and measurements of
3H retained on a filter using a
scintillation spectrometer.
Blood and Urine Analyses
Blood (,0.6 ml per mouse) was withdrawn by cardiac puncture
and transferred into BD Microtainer SST tubes (BD, Franklin
Lakes, NJ). The serum fraction was prepared by centrifugation in a
microcentrifuge after clotting occurred, immediately frozen in
liquid N2 and stored at 280uC. The levels of glucose, cholesterol,
sodium, potassium, chloride, calcium, phosphorus, blood urea
nitrogen, creatine, total protein, albumin, total bilirubin, aspartate
aminotransferase (AST), alanine aminotransferase (ALT), alkaline
phosphatase, c-glutamyltransferase (gamma gt), as well as the T3
and T4 hormones were determined by Phoenix Central
Laboratories (Everett, WA).
Urine was obtained by placing the external urethra over a test
tube. Urine samples collected from Ate1-deficient mice were
pooled and compared with pooled urine from Ate1-containing
mice. The levels of glucose, bilirubin, ketones, blood, protein,
urobilinogen, nitrite, leukocytes, as well as the pH and specific
gravity were determined using the Multistix 10 SG Reagent Strips
(Bayer, Tarry Town, NY).
Measurements of Body Temperature and Cold Sensitivity
Mice (housed at one mouse per cage, without bedding but with
food and water) were exposed to a 4uC environment for up to 6 hr
Their core body temperature was monitored every 30 min via a
rectal probe digital thermometer (Thermalert TH-8; Physitemp
Instruments., Clifton, NJ).
Measurements of
14C-Protein Uptake from
Gastrointestinal Tract
E. coli DH5a cells were grown in minimal M9 media
supplemented with 0.5% glucose and 50 mCi of
14C-amino acids
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14C-protein hydrolysate (Amersham)) until the
incorporation of ,70% of the added
14C amino acids. Cells were
lysed by one freeze/thaw cycle in PBS containing 1 mg/ml
lysozyme and incubated with RNase H and DNase I for 45 min at
37uC. A crude protein fraction was isolated by precipitation with
cold 10% TCA (CCl3COOH), and the pellet was washed with ice-
cold acetone. The pellet was redissolved in PBS, with a brief
sonication to facilitate solubilization. 0.2 ml of the resulting
sample, containing 260,000 cpm of
14C-labeled E. coli proteins
was fed to a mouse by oral gavage. Urine and feces was collected
at various times post-gavage. Total
14C was measured, using a
scintillation spectrometer, in feces, urine, and (eventually) in
mouse tissue samples that were collected either 48 hr or 15 days
post-gavage.
Measurements of Glucose Uptake
For glucose analyses, mice were fasted for 24 hr, then gavaged
with 50 mg glucose in 0.2 ml of water. Blood was collected
through the lateral tail vein at 15, 30, 60, 90, 120, and 360 min
post-gavage. Blood glucose levels were determined using the
OneTouch UltraMini Blood Glucose Monitoring System (Life-
Scan, Johnson and Johnson, Milpitas, CA).
Metabolic Analyses
The resting metabolic rate was determined at the Mouse
Physiology Laboratory in the Department of Physiology at the
Geffen School of Medicine, UCLA using indirect calorimetry as
previously described [43,44]. Single mice were placed into a
custom-made enclosed plexiglas chamber (25 cm612 cm67.5 cm,
with 4 room air intake vents and one outflow port) and allowed to
come to rest over a period of 30 min to 2 hr. Outflow of expired
gases was sampled by the gas analyzer and recorded using a
computerized acquisition system during a 30-min resting interval.
MRI Analyses of Mouse Brains
The procedures used were essentially the same as previously
described [45]. Mice were given an IP injection of 40 mg/kg of
Na-pentobarbital (Nembutal, Hospira, Inc., Lake Forest, IL).
Once fully anesthetized, mice were transcardially perfused with
4% formaldehyde in PBS. MRI analysis was performed by the
Caltech Brain Imaging Center. Briefly, mouse heads were excised
and postfixed in 4% formaldehyde/PBS overnight. Hair and skin
were removed from fixed heads, which were then soaked in 5 mM
Gadolinium-based MR contrast agent (Prohance Bracco Diag-
nostics, Durham, NC) for 10 days, to decrease the intrinsic tissue
relaxation rates and improve the MR acquisition efficiency. A
gradient echo sequence (TE/TR=8 msec/50 msec, 16 averages)
was used to acquire 3D data sets of the mice heads, using a Bruker
7T Biospec animal magnet system. Images were reconstructed
with an isotropic resolution of ,90 mm and analyzed using
Brainsuite 2 software [46].
Open-Field and Startle Response Tests
For the open-field activity measurements, individual mice were
placed into a square chamber (50 by 50 cm). Movements along the
x and y axes were tracked and analyzed using Ethovision software
(Noldus, Leesburg, VA) over 15-min intervals. Startle response
tests were carried out essentially as described previously [47].
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